Published 13 hours ago • loading... • Updated 13 hours ago

Obesity Treatment Has Revolutionized, but Attitudes Have Not – Doctor Says More Bariatric Surgery Should Be Done

Mentioning obesity can trigger a defensive reaction in the patient. In Sweden, more bariatric surgeries are performed and the patients have a lower body mass index on average than in Finland.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

5 Articles

KSML.fi – Keskisuomalainen

+4 Reposted by 4 other sources

Obesity Treatment Has Revolutionized, but Attitudes Have Not – Doctor Says More Bariatric Surgery Should Be Done

Mentioning obesity can trigger a defensive reaction in the patient. In Sweden, more bariatric surgeries are performed and the patients have a lower body mass index on average than in Finland.

13 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources5

Leaning Left0Leaning Right0Center0Last Updated3 hours agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

KSML.fi – Keskisuomalainen broke the news 13 hours ago on Sunday, November 15, 2026.

Sources are mostly out of (0)

Obesity Treatment Has Revolutionized, but Attitudes Have Not – Doctor Says More Bariatric Surgery Should Be Done

5 Articles

5 Articles

Obesity Treatment Has Revolutionized, but Attitudes Have Not – Doctor Says More Bariatric Surgery Should Be Done

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Novo's Investigational CagriSema, a GLP-1 and Amylin Analog, Demonstrated ~21% Average Weight Loss with Lower Doses in the REDEFINE 9 Trial, Presented at ObesityWeek® 2026 and Published in The Lancet Diabetes & Endocrinology

Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026

Lilly to Present New Data Across Zepbound, Foundayo, EloraTZP and Retatrutide at ObesityWeek 2026, Moving Obesity Care Beyond the Scale

CVS says GLP-1s save money when priced below $350 per month

Sleep Apnea: 45% Higher Risk of Alzheimer's - Affects More than 3 in 4 Obese People - iefimerida.gr

Over 40% of People with Diabetes Unaware of Condition – WHO

Similar News Topics

Similar News Topics

More stories like this

Novo's Investigational CagriSema, a GLP-1 and Amylin Analog, Demonstrated ~21% Average Weight Loss with Lower Doses in the REDEFINE 9 Trial, Presented at ObesityWeek® 2026 and Published in The Lancet Diabetes & Endocrinology

Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026

Lilly to Present New Data Across Zepbound, Foundayo, EloraTZP and Retatrutide at ObesityWeek 2026, Moving Obesity Care Beyond the Scale

CVS says GLP-1s save money when priced below $350 per month

Sleep Apnea: 45% Higher Risk of Alzheimer's - Affects More than 3 in 4 Obese People - iefimerida.gr

Over 40% of People with Diabetes Unaware of Condition – WHO

Obesity Treatment Has Revolutionized, but Attitudes Have Not – Doctor Says More Bariatric Surgery Should Be Done

5 Articles

5 Articles

Translate IconObesity Treatment Has Revolutionized, but Attitudes Have Not – Doctor Says More Bariatric Surgery Should Be Done

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Novo's Investigational CagriSema, a GLP-1 and Amylin Analog, Demonstrated ~21% Average Weight Loss with Lower Doses in the REDEFINE 9 Trial, Presented at ObesityWeek® 2026 and Published in The Lancet Diabetes & Endocrinology

Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026

Lilly to Present New Data Across Zepbound, Foundayo, EloraTZP and Retatrutide at ObesityWeek 2026, Moving Obesity Care Beyond the Scale

CVS says GLP-1s save money when priced below $350 per month

Sleep Apnea: 45% Higher Risk of Alzheimer's - Affects More than 3 in 4 Obese People - iefimerida.gr

Over 40% of People with Diabetes Unaware of Condition – WHO

Similar News Topics

Similar News Topics

More stories like this

Novo's Investigational CagriSema, a GLP-1 and Amylin Analog, Demonstrated ~21% Average Weight Loss with Lower Doses in the REDEFINE 9 Trial, Presented at ObesityWeek® 2026 and Published in The Lancet Diabetes & Endocrinology

Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026

Lilly to Present New Data Across Zepbound, Foundayo, EloraTZP and Retatrutide at ObesityWeek 2026, Moving Obesity Care Beyond the Scale

CVS says GLP-1s save money when priced below $350 per month

Sleep Apnea: 45% Higher Risk of Alzheimer's - Affects More than 3 in 4 Obese People - iefimerida.gr

Over 40% of People with Diabetes Unaware of Condition – WHO

Obesity Treatment Has Revolutionized, but Attitudes Have Not – Doctor Says More Bariatric Surgery Should Be Done

Bias Distribution

Factuality